Autologous, Engineered T Cells Targeting Tp53 R175H
Head And Neck Squamous Cell Carcinoma
Explore 249 assets in Head And Neck Squamous Cell Carcinoma →Floatz Rating
C37/100
Confidence
Indicative
Sponsor
AstraZeneca
Modality
Cell therapy
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05877599CT.gov A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Head And Neck Squamous Cell Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Autologous, Engineered T Cells Targeting Tp53 R175H (this asset) | AstraZeneca | P1 | C · 37 |
| Cis-Diamminedichloroplatinum Ii | Akeso | P3 | BB |
| Carboplatin | Akeso | P4 | BB |
| Irinotecan | Neonc Technologies, Inc. | P2 | BB |
| Capecitabine | Merck Sharp & Dohme LLC | P2 | BB |
| Tisotumab Vedotin | Seagen, a wholly owned subsidiary of Pfizer | P2 | BB |
| Pembrolizumab | UNC Lineberger Comprehensive Cancer Center | P4 | BB |
| Fluorouracilum | Akeso | P2 | BB |
| Cyclophosphamide | UNC Lineberger Comprehensive Cancer Center | P4 | BB |
+42 more in the Head And Neck Squamous Cell Carcinoma cohort
Other indications for Autologous, Engineered T Cells Targeting Tp53 R175H
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Colorectal Carcinoma | — | P1 | C · 39 |
| Pancreatic Adenocarcinoma | — | P1 | C · 39 |
| Non-Small Cell Lung Carcinoma | — | P1 | C · 36 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Autologous, Engineered T Cells Targeting Tp53 R175H in Head And Neck Squamous Cell Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/autologous-engineered-t-cells-targeting-tp53-r175h-head-and-neck-squamous-cell-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →